TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up
Brief Summary: BACKGROUND

Non-specific back and neck pain (BNP) dominates sick-listing. A program of cognitive-behavioral rehabilitation for subacute and chronic BNP was compared, with 18-month follow-up, with traditional primary care concerning sick-listing and health-care visits.

METHODS

After stratification to age (44 (years) and younger/45 and older) and subacute/chronic BNP (= full-time sick-listed 43-84/85-730 days respectively), 125 primary-care patients were randomized to a rehabilitation center or continued health-center care. Outcome measures were Return-to-work (=the proportion who regained work ability for at least 30 consecutive days), the proportion with Work ability at different time points, Total sick-listing (expressed in whole days) and the total number of Visits (to physicians, physiotherapists etc.) 1-18 months and corresponding six-month periods. For the analyses were used t-test, z-test, generalized estimating equations and a mixed, linear model.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
B: Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care, Drug: Antidepressants | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual Care | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stepped Care; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Antidepressants; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Intervention Type: DEVICE; Name: Total Disc Prosthesis; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Multidisciplinary rehabilitation program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up
Brief Summary: BACKGROUND

Non-specific back and neck pain (BNP) dominates sick-listing. A program of cognitive-behavioral rehabilitation for subacute and chronic BNP was compared, with 18-month follow-up, with traditional primary care concerning sick-listing and health-care visits.

METHODS

After stratification to age (44 (years) and younger/45 and older) and subacute/chronic BNP (= full-time sick-listed 43-84/85-730 days respectively), 125 primary-care patients were randomized to a rehabilitation center or continued health-center care. Outcome measures were Return-to-work (=the proportion who regained work ability for at least 30 consecutive days), the proportion with Work ability at different time points, Total sick-listing (expressed in whole days) and the total number of Visits (to physicians, physiotherapists etc.) 1-18 months and corresponding six-month periods. For the analyses were used t-test, z-test, generalized estimating equations and a mixed, linear model.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: tailored cognitive behavior therapy, Behavioral: standard care | Intervention Type: BEHAVIORAL; Name: tailored cognitive behavior therapy; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: standard care; Assigned to Arm(s): Arm 1
B: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
C: Arm Label: Pain Ed; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Ed, Other: Usual Care | Arm Label: CBT for Pain; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for Pain, Other: Usual Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Pain Ed; Assigned to Arm(s): Pain Ed | Intervention Type: BEHAVIORAL; Name: CBT for Pain; Assigned to Arm(s): CBT for Pain | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): CBT for Pain, Pain Ed, Usual Care
D: Arm Label: Lifestyles A; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles A | Arm Label: Lifestyle B; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyles B | Arm Label: Lifestyles C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyles C | Intervention Type: BEHAVIORAL; Name: Lifestyles A; Assigned to Arm(s): Lifestyles A | Intervention Type: BEHAVIORAL; Name: Lifestyles B; Assigned to Arm(s): Lifestyle B | Intervention Type: BEHAVIORAL; Name: Lifestyles C; Assigned to Arm(s): Lifestyles C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up
Brief Summary: BACKGROUND

Non-specific back and neck pain (BNP) dominates sick-listing. A program of cognitive-behavioral rehabilitation for subacute and chronic BNP was compared, with 18-month follow-up, with traditional primary care concerning sick-listing and health-care visits.

METHODS

After stratification to age (44 (years) and younger/45 and older) and subacute/chronic BNP (= full-time sick-listed 43-84/85-730 days respectively), 125 primary-care patients were randomized to a rehabilitation center or continued health-center care. Outcome measures were Return-to-work (=the proportion who regained work ability for at least 30 consecutive days), the proportion with Work ability at different time points, Total sick-listing (expressed in whole days) and the total number of Visits (to physicians, physiotherapists etc.) 1-18 months and corresponding six-month periods. For the analyses were used t-test, z-test, generalized estimating equations and a mixed, linear model.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: manual therapy, Other: exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise | Intervention Type: OTHER; Name: manual therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
C: Arm Label: 1 Manual Therapy Utrecht; Type: EXPERIMENTAL; Interventions: Other: Manual Therapy Utrecht | Arm Label: 2 Physical Therapy - Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: OTHER; Name: Manual Therapy Utrecht; Assigned to Arm(s): 1 Manual Therapy Utrecht | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): 2 Physical Therapy - Exercise Therapy
D: Arm Label: 9 months of chiropractic care and exercise; Type: EXPERIMENTAL; Interventions: Other: chiropractic, Behavioral: exercise | Arm Label: 3 months of chiropractic care and exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: chiropractic, Behavioral: exercise | Intervention Type: OTHER; Name: chiropractic; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up
Brief Summary: BACKGROUND

Non-specific back and neck pain (BNP) dominates sick-listing. A program of cognitive-behavioral rehabilitation for subacute and chronic BNP was compared, with 18-month follow-up, with traditional primary care concerning sick-listing and health-care visits.

METHODS

After stratification to age (44 (years) and younger/45 and older) and subacute/chronic BNP (= full-time sick-listed 43-84/85-730 days respectively), 125 primary-care patients were randomized to a rehabilitation center or continued health-center care. Outcome measures were Return-to-work (=the proportion who regained work ability for at least 30 consecutive days), the proportion with Work ability at different time points, Total sick-listing (expressed in whole days) and the total number of Visits (to physicians, physiotherapists etc.) 1-18 months and corresponding six-month periods. For the analyses were used t-test, z-test, generalized estimating equations and a mixed, linear model.


Options:
A: Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program
B: Arm Label: Specific resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck; Assigned to Arm(s): Specific resistance training
C: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up
Brief Summary: BACKGROUND

Non-specific back and neck pain (BNP) dominates sick-listing. A program of cognitive-behavioral rehabilitation for subacute and chronic BNP was compared, with 18-month follow-up, with traditional primary care concerning sick-listing and health-care visits.

METHODS

After stratification to age (44 (years) and younger/45 and older) and subacute/chronic BNP (= full-time sick-listed 43-84/85-730 days respectively), 125 primary-care patients were randomized to a rehabilitation center or continued health-center care. Outcome measures were Return-to-work (=the proportion who regained work ability for at least 30 consecutive days), the proportion with Work ability at different time points, Total sick-listing (expressed in whole days) and the total number of Visits (to physicians, physiotherapists etc.) 1-18 months and corresponding six-month periods. For the analyses were used t-test, z-test, generalized estimating equations and a mixed, linear model.


Options:
A: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment
B: Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral rehabilitation; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Traditional primary care; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Mod. functional restoration-Individ. dynamic back-muscle; Assigned to Arm(s): N/A
D: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder
Brief Summary: This study will compare the clinical efficacy and side effects of Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in patients currently experiencing a major depressive episode in the context of either unipolar or bipolar depression. The investigators will conduct a number of clinical and neuropsychological tests to assess clinical and cognitive response to treatment. The investigators hypothesize that:

1. MST and ECT will have similar antidepressant efficacy.
2. MST will have less post-treatment amnesia than ECT as reflected in primary measures of anterograde and retrograde amnesia following the acute treatment phase.
3. At follow up, MST will show a lesser degree of persisting deficit in measures of retrograde amnesia than ECT.


Options:
A: Arm Label: Magnetic seizure therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic seizure therapy | Arm Label: Electroconvulsive therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive therapy | Intervention Type: DEVICE; Name: Magnetic seizure therapy; Assigned to Arm(s): Magnetic seizure therapy | Intervention Type: DEVICE; Name: Electroconvulsive therapy; Assigned to Arm(s): Electroconvulsive therapy
B: Arm Label: MST; Type: EXPERIMENTAL; Interventions: Device: Magstim Theta | Arm Label: ECT; Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron | Intervention Type: DEVICE; Name: Thymatron; Assigned to Arm(s): ECT | Intervention Type: DEVICE; Name: Magstim Theta; Assigned to Arm(s): MST
C: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: MagVenture MagPro MST | Arm Label: RUL ECT; Type: ACTIVE_COMPARATOR; Interventions: Biological: RUL ECT | Intervention Type: DEVICE; Name: MagVenture MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: BIOLOGICAL; Name: RUL ECT; Assigned to Arm(s): RUL ECT
D: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive Therapy | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: DEVICE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy (ECT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with active ulcerative colitis (UC) (sores in the colon).


Options:
A: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Golimumab 1 milligram (mg) per kilogram (kg); Type: EXPERIMENTAL; Interventions: Drug: Golimumab 1 mg per kg | Arm Label: Golimumab 2 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 2 mg per kg | Arm Label: Golimumab 4 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 4 mg per kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab 1 mg per kg; Assigned to Arm(s): Golimumab 1 milligram (mg) per kilogram (kg) | Intervention Type: DRUG; Name: Golimumab 2 mg per kg; Assigned to Arm(s): Golimumab 2 mg per kg | Intervention Type: DRUG; Name: Golimumab 4 mg per kg; Assigned to Arm(s): Golimumab 4 mg per kg
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tralokinumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tralokinumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 9 mg | Arm Label: 3: Entocort EC® 3 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Entocort EC® 3 mg | Arm Label: 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Entocort EC® 3 mg, 4: Placebo | Intervention Type: DRUG; Name: Budesonide MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: Budesonide MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Entocort EC® 3 mg; Assigned to Arm(s): 3: Entocort EC® 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4: Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
Brief Summary: RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.

PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
C: Arm Label: Patients taking the drug Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Patients taking the placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Patients taking the drug Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Patients taking the placebo
D: Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 4; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy
Brief Summary: RATIONALE: Duloxetine may lessen peripheral neuropathy caused by chemotherapy. It is not yet known whether duloxetine is more effective than a placebo in treating peripheral neuropathy caused by chemotherapy.

PURPOSE: This randomized phase III trial is studying duloxetine to see how well it works compared with a placebo in treating peripheral neuropathy caused by chemotherapy in patients with cancer.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: E; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): B | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): E
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
D: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)

Answer: D